REPORT ID 6225

United States Glomerulonephritis Treatment Market Report 2019

Publish Date
2019
Pages
109
Format
Electronic (PDF)

In this report, the United States Glomerulonephritis Treatment market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Glomerulonephritis Treatment in these regions, from   2019 to 2025 (forecast).

United States Glomerulonephritis Treatment market competition by top manufacturers/players, with Glomerulonephritis Treatment sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Achillion Pharmaceuticals Inc
    Anthera Pharmaceuticals Inc
    Biogen Inc
    Bristol-Myers Squibb Company
    Cellmid Ltd
    ChemoCentryx Inc
    Complexa Inc
    Dimerix Bioscience Pty Ltd
    GlaxoSmithKline Plc
    Merck KGaA
    Omeros Corp
    Pfizer Inc
    Pharmalink AB
    Ra Pharmaceuticals Inc
    Retrophin Inc
    Rigel Pharmaceuticals Inc
    Shire Plc
    Visterra Inc

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    ACH-5228
    AMY-101
    Atacicept
    Avacopan
    AVX-002
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Home Care
    Clinic
    Hospital

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Glomerulonephritis Treatment Market  Report 2019
1 Glomerulonephritis Treatment Overview
    1.1 Product Overview and Scope of Glomerulonephritis Treatment
    1.2 Classification of Glomerulonephritis Treatment by Product Category
        1.2.1 United States Glomerulonephritis Treatment Market Size (Sales Volume) Comparison by Type ( 2014-2024)
        1.2.2 United States Glomerulonephritis Treatment Market Size (Sales Volume) Market Share by Type (Product Category)  in 2018
        1.2.3 ACH-5228
        1.2.4 AMY-101
        1.2.5 Atacicept
        1.2.6 Avacopan
        1.2.7 AVX-002
    1.3 United States Glomerulonephritis Treatment Market by Application/End Users
        1.3.1 United States Glomerulonephritis Treatment Market Size (Consumption) and Market Share Comparison by Application ( 2014-2024)
        1.3.2 Home Care
        1.3.3 Clinic
        1.3.4 Hospital
    1.4 United States Glomerulonephritis Treatment Market by Region
        1.4.1 United States Glomerulonephritis Treatment Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 The West Glomerulonephritis Treatment Status and Prospect ( 2014-2024)
        1.4.3 Southwest Glomerulonephritis Treatment Status and Prospect ( 2014-2024)
        1.4.4 The Middle Atlantic Glomerulonephritis Treatment Status and Prospect ( 2014-2024)
        1.4.5 New England Glomerulonephritis Treatment Status and Prospect ( 2014-2024)
        1.4.6 The South Glomerulonephritis Treatment Status and Prospect ( 2014-2024)
        1.4.7 The Midwest Glomerulonephritis Treatment Status and Prospect ( 2014-2024)
    1.5 United States Market Size (Value and Volume) of Glomerulonephritis Treatment ( 2014-2024)
        1.5.1 United States Glomerulonephritis Treatment Sales and Growth Rate ( 2014-2024)
        1.5.2 United States Glomerulonephritis Treatment Revenue and Growth Rate ( 2014-2024)

2 United States Glomerulonephritis Treatment Market Competition by Players/Suppliers
    2.1 United States Glomerulonephritis Treatment Sales and Market Share of Key Players/Suppliers ( 2014-2019)
    2.2 United States Glomerulonephritis Treatment Revenue and Share by Players/Suppliers ( 2014-2019)
    2.3 United States Glomerulonephritis Treatment Average Price by Players/Suppliers ( 2014-2019)
    2.4 United States Glomerulonephritis Treatment Market Competitive Situation and Trends
        2.4.1 United States Glomerulonephritis Treatment Market Concentration Rate
        2.4.2 United States Glomerulonephritis Treatment Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Glomerulonephritis Treatment Manufacturing Base Distribution, Sales Area, Product Type

3 United States Glomerulonephritis Treatment Sales (Volume) and Revenue (Value) by Region ( 2014-2019)
    3.1 United States Glomerulonephritis Treatment Sales and Market Share by Region ( 2014-2019)
    3.2 United States Glomerulonephritis Treatment Revenue and Market Share by Region ( 2014-2019)
    3.3 United States Glomerulonephritis Treatment Price by Region ( 2014-2019)

4 United States Glomerulonephritis Treatment Sales (Volume) and Revenue (Value) by Type (Product Category) ( 2014-2019)
    4.1 United States Glomerulonephritis Treatment Sales and Market Share by Type (Product Category) ( 2014-2019)
    4.2 United States Glomerulonephritis Treatment Revenue and Market Share by Type ( 2014-2019)
    4.3 United States Glomerulonephritis Treatment Price by Type ( 2014-2019)
    4.4 United States Glomerulonephritis Treatment Sales Growth Rate by Type ( 2014-2019)

5 United States Glomerulonephritis Treatment Sales (Volume) by Application ( 2014-2019)
    5.1 United States Glomerulonephritis Treatment Sales and Market Share by Application ( 2014-2019)
    5.2 United States Glomerulonephritis Treatment Sales Growth Rate by Application ( 2014-2019)
    5.3 Market Drivers and Opportunities

6  United States Glomerulonephritis Treatment Players/Suppliers Profiles and Sales Data
    6.1 Achillion Pharmaceuticals Inc
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Glomerulonephritis Treatment Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.1.4 Main Business/Business Overview
    6.2 Anthera Pharmaceuticals Inc
        6.2.2 Glomerulonephritis Treatment Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.2.4 Main Business/Business Overview
    6.3 Biogen Inc
        6.3.2 Glomerulonephritis Treatment Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Biogen Inc Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.3.4 Main Business/Business Overview
    6.4 Bristol-Myers Squibb Company
        6.4.2 Glomerulonephritis Treatment Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Bristol-Myers Squibb Company Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.4.4 Main Business/Business Overview
    6.5 Cellmid Ltd
        6.5.2 Glomerulonephritis Treatment Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Cellmid Ltd Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.5.4 Main Business/Business Overview
    6.6 ChemoCentryx Inc
        6.6.2 Glomerulonephritis Treatment Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 ChemoCentryx Inc Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.6.4 Main Business/Business Overview
    6.7 Complexa Inc
        6.7.2 Glomerulonephritis Treatment Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Complexa Inc Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.7.4 Main Business/Business Overview
    6.8 Dimerix Bioscience Pty Ltd
        6.8.2 Glomerulonephritis Treatment Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.8.4 Main Business/Business Overview
    6.9 GlaxoSmithKline Plc
        6.9.2 Glomerulonephritis Treatment Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 GlaxoSmithKline Plc Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.9.4 Main Business/Business Overview
    6.10 Merck KGaA
        6.10.2 Glomerulonephritis Treatment Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Merck KGaA Glomerulonephritis Treatment Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.10.4 Main Business/Business Overview
    6.11 Omeros Corp
    6.12 Pfizer Inc
    6.13 Pharmalink AB
    6.14 Ra Pharmaceuticals Inc
    6.15 Retrophin Inc
    6.16 Rigel Pharmaceuticals Inc
    6.17 Shire Plc
    6.18 Visterra Inc

7 Glomerulonephritis Treatment Manufacturing Cost Analysis
    7.1 Glomerulonephritis Treatment Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Glomerulonephritis Treatment

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Glomerulonephritis Treatment Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Glomerulonephritis Treatment Major Manufacturers  in 2018
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Glomerulonephritis Treatment Market Size (Value and Volume) Forecast ( 2019-2025)
    11.1 United States Glomerulonephritis Treatment Sales Volume, Revenue Forecast ( 2019-2025)
    11.2 United States Glomerulonephritis Treatment Sales Volume Forecast by Type ( 2019-2025)
    11.3 United States Glomerulonephritis Treatment Sales Volume Forecast by Application ( 2019-2025)
    11.4 United States Glomerulonephritis Treatment Sales Volume Forecast by Region ( 2019-2025)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer